Alcobra Ltd. (ADHD) Given Consensus Recommendation of “Hold” by Brokerages
Alcobra Ltd. (NASDAQ:ADHD) has earned a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $1.54.
Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Tuesday, July 18th. WBB Securities upgraded Alcobra from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Monday, October 9th. Finally, Roth Capital cut Alcobra from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $4.00 to $1.00 in a report on Friday, September 29th.
A hedge fund recently raised its stake in Alcobra stock. Citadel Advisors LLC grew its position in Alcobra Ltd. (NASDAQ:ADHD) by 7,251.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,114 shares of the biotechnology company’s stock after purchasing an additional 101,514 shares during the period. Citadel Advisors LLC’s holdings in Alcobra were worth $114,000 at the end of the most recent quarter. Institutional investors and hedge funds own 29.76% of the company’s stock.
Alcobra (ADHD) opened at 1.57 on Wednesday. The company’s market cap is $43.27 million. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.14. Alcobra has a 12-month low of $0.83 and a 12-month high of $2.58.
Alcobra (NASDAQ:ADHD) last issued its earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. On average, equities research analysts forecast that Alcobra will post ($0.77) earnings per share for the current fiscal year.
Alcobra Company Profile
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.